Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection

Journal of Viral Hepatitis

Volumn 17, Issue 3, 2010, Pages 192-200

  Bekker, V ^a   Chanock, S J ^a,b   Yeager, M ^b   Hutchinson, A A ^b   Von Hahn, T ^c   Chen, S ^d   Xiao, N ^b   Dotrang, M ^e   Brown, M ^b   Busch, M P ^f,g   Edlin, B R ^f,h   Rice, C M ^c   O'Brien, T R ^b  

^a Center for Cancer Research   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e CSC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Claudin 1; Epidemiology; Genetic; Susceptibility; Viral receptor

Indexed keywords

CLAUDIN 1;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EUROPEAN AMERICAN; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION SENSITIVITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CROSS-SECTIONAL STUDIES; DRUG USERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEPATITIS C; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 75149170527     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01166.x     Document Type: Article

References (26)

1. NIH. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002 19: 1 46.
2. Di Bisceglie AM, Lyra AC, Schwartz M et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003 98: 2060 2063.
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007 13: 2436 2441.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347: 975 982.
5. Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 2006 44: 527 535.
6. Evans MJ, von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007 446: 801 805.
7. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and-2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998 141: 1539 1550.
8. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006 6: 186.
9. Kramer F, White K, Kubbies M, Swisshelm K, Weber BH. Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum Genet 2000 107: 249 256.
10. Feldmeyer L, Huber M, Fellmann F, Beckmann JS, Frenk E, Hohl D. Confirmation of the origin of NISCH syndrome. Hum Mutat 2006 27: 408 410.
11. Hadj-Rabia S, Baala L, Vabres P et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology 2004 127: 1386 1390.
12. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001 357: 1397 1401.
13. Seal KHKA, Lorvick J, Gee L, Tsui JI, Edlin BR. Among injection drug users, interest is high, but access low to HCV antiviral therapy. J Gen Intern Med 2005 20 (Suppl. 1 1.
14. Atkinson J, Edlin BR, Engels EA et al. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis 2003 187: 974 981.
15. Helgadottir A, Manolescu A, Helgason A et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006 38: 68 74.
16. Faraone SV, Matise T, Svrakic D et al. Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium. Am J Med Genet 1998 81: 290 295. (Pubitemid 28294809)
17. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001 27: 234 236.
18. Packer BR, Yeager M, Burdett L et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006 34: D617 D621.
19. Bekker V, O'Brien JR, Chanock S. Population genetics and comparative genetics of CLDN1, a gene involved in hepatitis C virus entry. Hum Hered 2009 67: 206 216.
20. Tseng FC, O'Brien TR, Zhang M et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 2007 46: 666 671.
21. Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007 449: 851 861.
22. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res 2005 15: 1592 1593.
23. Tseng FC, Edlin BR, Zhang M et al. The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. J Viral Hepat 2008 15: 690 698.
24. Mizukoshi E, Eisenbach C, Edlin BR et al. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008 198: 203 212.
25. Little J, Bradley L, Bray MS et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002 156: 300 310.
26. Chanock SJ, Manolio T, Boehnke M et al. Replicating genotype-phenotype associations. Nature 2007 447: 655 660.